共 50 条
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
被引:154
|作者:
Guenther, Thomas
[1
]
Tulipano, Giovanni
[2
]
Dournaud, Pascal
[3
]
Bousquet, Corinne
[4
]
Csaba, Zsolt
[3
]
Kreienkamp, Hans-Juergen
[5
]
Lupp, Amelie
[1
]
Korbonits, Marta
[6
]
Castano, Justo P.
[7
,8
,9
,10
]
Wester, Hans-Juergen
[11
]
Culler, Michael
[12
]
Melmed, Shlomo
[13
]
Schulz, Stefan
[1
]
机构:
[1] Friedrich Schiller Univ, Jena Univ Hosp, Inst Pharmacol & Toxicol, Jena, Germany
[2] Univ Brescia, Dept Mol & Translat Med, Unit Pharmacol, Brescia, Italy
[3] Univ Paris Diderot, PROTECT, INSERM, Sorbonne Paris Cite, Paris, France
[4] Univ Toulouse III Paul Sabatier, Canc Res Ctr Toulouse, INSERM UMR 1037, Toulouse, France
[5] Univ Med Ctr Hamburg Eppendorf, Inst Human Genet, Hamburg, Germany
[6] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med, Ctr Endocrinol, London, England
[7] Maimonides Inst Biomed Res Cordoba, Cordoba, Spain
[8] Univ Cordoba, Dept Cell Biol Physiol & Immunol, Cordoba, Spain
[9] Reina Sofia Univ Hosp, Cordoba, Spain
[10] CIBER Fisiopatol Obesidad & Nutr, Cordoba, Spain
[11] Tech Univ Munich, Pharmaceut Radiochem, Munich, Germany
[12] Culler Consulting LLC, Hopkinton, MA USA
[13] Cedars Sinai Med Ctr, Dept Med, Pituitary Ctr, Los Angeles, CA 90048 USA
基金:
美国国家卫生研究院;
英国医学研究理事会;
关键词:
PROTEIN-COUPLED RECEPTORS;
MEDULLARY-THYROID CARCINOMA;
MESSENGER-RIBONUCLEIC-ACID;
GROWTH-HORMONE-RELEASE;
PITUITARY-TUMOR CELLS;
DISTINCT SIGNALING PATHWAYS;
IN-VITRO CHARACTERIZATION;
NEOPLASTIC HUMAN TISSUES;
PHOSPHOTYROSINE PHOSPHATASE-ACTIVITY;
PREOPERATIVE OCTREOTIDE TREATMENT;
D O I:
10.1124/pr.117.015388
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Somatostatin, also known as somatotropinrelease inhibitory factor, is a cyclopeptide that exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its physiologic functions are mediated by five G protein- coupled receptors (GPCRs) called somatostatin receptor (SST) 1-5. These five receptors share common structural features and signaling mechanisms but differ in their cellular and subcellular localization andmode of regulation. SST2 and SST5 receptors have evolved as primary targets for pharmacological treatment of pituitary adenomas and neuroendocrine tumors. In addition, SST2 is a prototypical GPCR for the development of peptide-based radiopharmaceuticals for diagnostic and therapeutic interventions. This review article summarizes findings published in the last 25 years on the physiology, pharmacology, and clinical applications related to SSTs. We also discuss potential future developments and propose a new nomenclature.
引用
收藏
页码:763 / 835
页数:73
相关论文